N/A N=48 Visual Restoration for Hemianopia
Stroke Induced Vision Loss · Hemianopia · Quadrantanopia
Primary: 24-2 Humphrey PMD Change From Baseline to 6-month Post-training Timepoint — 0.84; 0.10; 0.58; 0.12 decibels
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Rekovelle PK Trial in Chinese Women
Infertility
Primary: Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC) — 41.3; 62.9; 83.1 h*ng/mL
Phase 2 N=20 LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Non-Small-Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 by Investigator Assessment — 25.0 Percentage of participants
N/A N=220 Management Strategies for Patients With Low Back Pain and Sciatica
Low Back Pain · Sciatica · Physical Therapy
Primary: Change From Baseline in Oswestry Disability Index — -8.8; -17.0; -17.0; -22.4 units on a scale
Phase 4 N=69 Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block
ACL Surgery
Primary: Total Opioid Consumption Intraop Measured by Amounts of Morphine Equivalents — 23.21; 18.93 milligrams of morphine equivalents
N/A N=1,909 Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril
Arterial Hypertension · CHD - Coronary Heart Disease
Primary: The Mean SBP Changes (mm Hg) at the Visit 3 vs. Baseline — 31.5 mm Hg
Phase 2 N=188 Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects
Pseudomonas Aeruginosa
Primary: Percentage of Participants With Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa — 18.1; 12.5; 22.4 Percentage of participants — p=0.491
Phase 3 N=580 Confirmatory Study of DSP-5423P in Patients With Schizophrenia
Schizophrenia
Primary: Change in PANSS Total Score From Baseline at Week 6 — 99.5; 101.6; 101.5; -10.8 units on a scale — p=0.007
Phase 2 N=162 Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Breast Cancer
Primary: 2-Year Treatment Discontinuation Rate — 31 percentage of participants — p=0.0011
Phase 3 N=1,162 Safety and Efficacy Study in Adult Subjects With Acute Migraines
Migraine, With or Without Aura
Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 19.2; 14.2 percentage of participants — p=0.0298
Phase 3 N=653 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Primary: Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall. — 0.54; 0.24; 1.30; 0.77 score on a scale
Phase 2 N=302 A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
Nocturia
Primary: Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment — -1.06; -0.99; -0.89; -0.80 nocturnal voids
Phase 2 N=22 Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Event (SAEs) — 6; 15; 2; 0 Participants
N/A N=100 Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate and Severe Nasolabial Folds
Nasolabial Folds in Chinese Population
Primary: Mean Change From Baseline in Wrinkle Severity Rating Scale (WSRS) at 6 Months — -0.03; 0.03 units on a scale
Phase 4 N=60 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Myocardial Infarction
Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL